Interestingly, lowering the molar activity of the radiolabelled conjugate from 1200 MBq/nmol to 8 MBq/nmol resulted in better kidney-to-tumour ratios (11.4 compared to 1.4, respectively) in subcutaneous murine PSMA-positive human prostate carcinoma xenografts. This evidence concerns the gene FOLH1 and prostate carcinoma.